{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:14:54Z","timestamp":1772205294356,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ajoc.2022.101309","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T21:28:04Z","timestamp":1643059684000},"page":"101309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-2941","authenticated-orcid":false,"given":"Federico","family":"Di Staso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Silvio Di Staso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-0171","authenticated-orcid":false,"given":"Irene","family":"Gattazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ciancaglini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-0722","authenticated-orcid":false,"given":"Gianluca","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajoc.2022.101309_bib1","first-page":"323","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol Allergy Clin"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101309_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101309_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"12","key":"10.1016\/j.ajoc.2022.101309_bib4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101309_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101309_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101309_bib7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2013clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101309_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13134","article-title":"Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin","volume":"32","author":"Sernicola","year":"2019","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101309_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101309_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MJT.0b013e31818a975c","article-title":"Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption","volume":"16","author":"Pariser","year":"2009","journal-title":"Am J Therapeut"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101309_bib11","first-page":"488","article-title":"Management of dupilumab\u2010associated conjunctivitis in atopic dermatitis","volume":"17","author":"Aszodi","year":"2019","journal-title":"JDDG J der Deutschen Dermatol Gesellschaft"},{"issue":"7490","key":"10.1016\/j.ajoc.2022.101309_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.38376.439653.D3","article-title":"Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials","volume":"330","author":"Ashcroft","year":"2005","journal-title":"BMJ"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362200055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362200055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:02:03Z","timestamp":1762527723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245199362200055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":12,"alternative-id":["S245199362200055X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101309","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101309"}}